Diastolic Dysfunction Unveiling Cardiac Light-Chain Amyloidosis: A Case Report

Main Article Content

Somesh Saha Ritwick Mondal Shramana Deb Biswarup Sarkar Julián Benito-Leon

Abstract

Background: Cardiac light-chain amyloidosis represents a critical component of this multi-systemic disease, significantly impacting prognosis. The extent of cardiac free light-chain deposition is the primary determinant of survival.


Case Presentation 
We report the case of a 67-year-old male with a 10-year history of diabetes mellitus and arterial hypertension who presented with a two-day history of chest discomfort and difficulty lying down or sleeping, along with a two-month history of progressively worsening exertional dyspnea. On examination, the patient exhibited low blood pressure. A 12-lead electrocardiogram revealed poor R-wave progression and left ventricular hypertrophy. Further evaluation using 2D echocardiography demonstrated significant concentric left ventricular hypertrophy, a restrictive filling pattern, and mild pericardial effusion. Cardiac magnetic resonance imaging, nuclear imaging, and biopsy confirmed the diagnosis of cardiac light-chain amyloidosis.


Conclusion: Timely recognition and a high index of suspicion are essential for the early diagnosis of cardiac amyloidosis. Prompt diagnosis enables the initiation of definitive therapy, which may halt disease progression and significantly improve prognosis.

Keywords: Light chain, amyloidosis, cardiac amyloidosis, hypertrophy, Heart failure

Article Details

How to Cite
SAHA, Somesh et al. Diastolic Dysfunction Unveiling Cardiac Light-Chain Amyloidosis: A Case Report. Medical Research Archives, [S.l.], v. 12, n. 12, dec. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6168>. Date accessed: 06 jan. 2025. doi: https://doi.org/10.18103/mra.v12i12.6168.
Section
Case Reports

References

1. Kittleson M, Panjrath G, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction. J Am Coll Cardiol. 2023; 81(18):1835-1878. doi:10.1016/j.jacc.2023.03.3931

2. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68(12):1323-1341. doi:10.1016/j.jacc.2016.06.053

3. Manolis AS, Manolis AA, Manolis TA, Melita H. Cardiac amyloidosis: An underdiagnosed/ underappreciated disease. Eur J Intern Med. 2019;67:1-13. doi:10.1016/j.ejim.2019.07.022

4. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596. doi:10.1056/NEJMra023144

5. Porcari A, Falco L, Lio V, et al. Cardiac amyloidosis: do not forget to look for it. Eur Heart J Suppl. 2020;22(Suppl E):E142-E147. doi:10.1093/eurheartj/suaa080

6. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113-122. doi:10.1016/j.jchf.2013.11.004

7. Porcari A, Pagura L, Rossi M, et al. Light-chain cardiac amyloidosis: A case report of extraordinary sustained pathological response to cyclophosphamide, bortezomib, and dexamethasone combined therapy. Eur Heart J Case Rep. 2022;6(4):ytac1307. doi:10.1093/ehjcr/ytac1307

8. Merlo M, Porcari A, Pagura L, et al. A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: Study design and patients’ characterization—The first insight from the AC-TIVE Study. Eur J Prev Cardiol. 2022;29(5):e173-e177. doi:10.1093/eurjpc/zwab127

9. Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev. 2015;20(2):133-144. doi:10.1007/s10741-014-9470-7

10. Cai S, Haghbayan H, Chan KKW, et al. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis. Int J Cardiol. 2024. doi:10.1016/j.ijcard.2024.131892. PMID: 38382853

11. Dorbala S, Cuddy S, Falk RH. How to Image Cardiac Amyloidosis: A Practical Approach. JACC Cardiovasc Imaging. 2020. doi:10.1016/j.jcmg.2019.07.015. PMID: 31607664; PMCID: PMC7148180

12. Isomali D, Mohty D, Grogan M, et al. Treatment of amyloid light chain cardiac amyloidosis: Systematic review and future directions. Clin Adv Hematol Oncol. 2022. PMID: 36206073

13. Palladini G, Milani P. Diagnosis and Treatment of AL Amyloidosis. Drugs. 2023 Feb;83(3):203-216. doi: 10.1007/s40265-022-01830-z. Epub 2023 Jan 18. PMID: 36652193.

14. Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022. doi:10.1002/ajh.26569. PMID: 35429180

15. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020 Dec 3;136(23):2620-2627. doi: 10.1182/blood.2020006913. PMID: 33270858.

16. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017 Dec;84(12 Suppl 3):12-26. doi: 10.3949/ccjm.84.s3.02. PMID: 29257735.